Visiomed Group buy melinda
Start price
02.08.18
/
50%
€13.26
Target price
18.12.18
€18.00
Performance (%)
-74.21%
End price
18.12.18
€3.42
Summary
This prediction ended on 18.12.18 with a price of €3.42. Massive losses of -74.21% were the result for the BUY prediction by melinda. melinda has a follow-up prediction for Visiomed Group where he still thinks Visiomed Group is a Buy. melinda has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Visiomed Group | 2.451% | 2.451% | -43.052% | 45.950% |
iShares Core DAX® | -1.114% | 3.430% | 25.966% | 25.039% |
iShares Nasdaq 100 | 1.816% | 6.911% | 30.390% | 48.139% |
iShares Nikkei 225® | 2.113% | 5.501% | 23.404% | 11.979% |
iShares S&P 500 | 2.038% | 5.327% | 30.881% | 46.982% |
According to melinda what are the pros and cons of Visiomed Group for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread Visiomed Group diskutieren
santé
(AOF) - Visiomed Group annonce que les Laboratoires Visiomed, branche dédiée aux produits de santé familiale commercialisés en pharmacie, vient de signer un projet d'acquisition de « deux marques centenaires leader en pharmacies dans leur domaine ». Ces marques, qui ne sont pas nommées, étaient détenues jusqu'à présent par les laboratoires Omega Pharma France et les Laboratoires Omega Pharma Belgium, filiales du groupe pharmaceutique américain Perrigo
(Vom Mitglied beendet)
Current prediction by melinda for Visiomed Group
Visiomed Group
Start price
Target price
Perf. (%)
€0.25
02.11.23
02.11.23
€0.50
02.11.24
02.11.24
-16.47%
03.10.24
03.10.24
Could be worthwhile Investment >10% per year
Stopped prediction by melinda for Visiomed Group
Visiomed Group
Start price
Target price
Perf. (%)
€0.17
24.01.22
24.01.22
-
24.01.23
24.01.23
116.40%
25.01.23
25.01.23
Could be worthwhile Investment >10% per year
Visiomed Group
Start price
Target price
Perf. (%)
€0.86
25.01.21
25.01.21
€1.00
25.01.22
25.01.22
-80.01%
24.01.22
24.01.22
Could be worthwhile Investment >10% per year